Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus oxaliplatin-based chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2100046202Phase 4Recruiting
- Sponsor
- First Hospital of Nanping
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, oxaliplatin, capecitabine and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Hospital of Nanping. Primary endpoints: Progression-free survival and Incidence of postoperative liver metastasis. Started Jun 2021; status: recruiting.
02
Drugs
sintilimaboxaliplatincapecitabinepaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100046202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046202.